Price Alert

Aquestive Therapeutics In... (AQST)

NASDAQ: AQST · Real-Time Price · USD

5.42

0.36 (7.11%)

At close: Sep 05, 2025, 3:59 PM

5.39

-0.55%

After-hours: Sep 05, 2025, 07:56 PM EDT

Aquestive Therapeutics Statistics

Share Statistics

Aquestive Therapeutics has 99.73M shares outstanding. The number of shares has increased by 9.08% in one year.

Shares Outstanding	99.73M
Shares Change (YoY)	9.08%
Shares Change (QoQ)	0.46%
Owned by Institutions (%)	46.34%
Shares Floating	94.93M
Failed to Deliver (FTD) Shares	605
FTD / Avg. Volume	0.04%

Short Selling Information

The latest short interest is 8.41M, so 6.95% of the outstanding shares have been sold short.

Short Interest	8.41M
Short % of Shares Out	6.95%
Short % of Float	7.98%
Short Ratio (days to cover)	5.8

Valuation Ratios

The PE ratio is -7 and the forward PE ratio is -9.04. Aquestive Therapeutics's PEG ratio is -0.02.

PE Ratio	-7
Forward PE	-9.04
PS Ratio	5.36
Forward PS	8.8
PB Ratio	-5.13
P/FCF Ratio	-8.6
PEG Ratio	-0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Aquestive Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.68, with a Debt / Equity ratio of -0.63.

Current Ratio	4.68
Quick Ratio	4.36
Debt / Equity	-0.63
Debt / EBITDA	-1.43
Debt / FCF	-1.06
Interest Coverage	-1.83

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$405.36K
Profits Per Employee	$-310.82K
Employee Count	142
Asset Turnover	0.57
Inventory Turnover	2.96

Taxes

Income Tax	-14K
Effective Tax Rate	0.03%

Stock Price Statistics

The stock price has increased by 29.67% in the last 52 weeks. The beta is 1.82, so Aquestive Therapeutics's price volatility has been higher than the market average.

Beta	1.82
52-Week Price Change	29.67%
50-Day Moving Average	3.96
200-Day Moving Average	3.38
Relative Strength Index (RSI)	80.05
Average Volume (20 Days)	1,553,235

Income Statement

In the last 12 months, Aquestive Therapeutics had revenue of 57.56M and earned -44.14M in profits. Earnings per share was -0.51.

Revenue	57.56M
Gross Profit	39.69M
Operating Income	-30.77M
Net Income	-44.14M
EBITDA	-26.62M
EBIT	-27.33M
Earnings Per Share (EPS)	-0.51

Full Income Statement

Balance Sheet

The company has 71.55M in cash and 38M in debt, giving a net cash position of 33.54M.

Cash & Cash Equivalents	71.55M
Total Debt	38M
Net Cash	33.54M
Retained Earnings	-363.21M
Total Assets	93.7M
Working Capital	58.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -35.76M and capital expenditures -159K, giving a free cash flow of -35.92M.

Operating Cash Flow	-35.76M
Capital Expenditures	-159K
Free Cash Flow	-35.92M
FCF Per Share	-0.41

Full Cash Flow Statement

Margins

Gross margin is 68.95%, with operating and profit margins of -53.46% and -76.68%.

Gross Margin	68.95%
Operating Margin	-53.46%
Pretax Margin	-76.7%
Profit Margin	-76.68%
EBITDA Margin	-46.24%
EBIT Margin	-53.46%
FCF Margin	-62.4%

Dividends & Yields

AQST does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AQST is $9.5, which is 75.3% higher than the current price. The consensus rating is "Buy".

Price Target	$9.5
Price Target Difference	75.3%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-5.09
Piotroski F-Score	1